Delhi chemists told to substantiate medicine discounts and drop misleading 60–80% claims
Delhi’s drug control department has warned licensed pharmacies against exaggerated or unverifiable medicine-discount advertising. Retailers may sell below MRP, but advertised discounts must be genuine, transparent and supported by sale bills and purchase records.
What happened
Delhi chemist shops and medical stores · Delhi’s drug control department warned licensed pharmacies against exaggerated or unverifiable medicine discount
Key facts
- 60-80%
- 60%
- 70%
- 80%
Why this matters
Prioritize targets with disciplined pricing governance and verifiable promotional data, as regulatory exposure may complicate pharmacy-retail valuations and integration.
What to watch
- Named notices, fines, licence actions or inspection data from Delhi’s drug-control department.
- Whether enforcement covers e-pharmacies, quick-commerce medicine sellers, aggregators and third-party marketplace ads.
- Copycat advisories from drug regulators in Maharashtra, Karnataka, Telangana, Uttar Pradesh or central authorities.
- Changes in advertised discount depth, coupon usage, conversion rates and customer-acquisition costs at pharmacy chains.
- Court challenges or industry-association representations seeking clearer rules on MRP discount advertising.
- Audit all medicine-discount creatives against invoice-level purchase and sale records, including app, website, storefront and marketplace listings.
- Replace maximum-discount claims with SKU-specific, time-bound and clearly qualified offers.
- Build approval workflows linking marketing claims to inventory, pricing and compliance documentation.
- Increase promotion of non-drug categories, loyalty benefits, delivery subscriptions and diagnostics where discount messaging carries lower regulatory risk.
- Prepare a Delhi-specific response plan for inspections, notices, customer complaints and takedown requests.